此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他持牌證券交易商、 銀行經理、律師、專業會計師或其他專業顧問。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 建議委任非執行董事； 及 2026年第一次臨時股東會通告 董事會函件載於本通函第3至6頁。 本公司將於2026年2月12日（星期四）下午二時正召開臨時股東會，會議將由假座中國北京市大興區大興生 物醫藥產業基地寶參南街12號院會議室舉行的現場會議結合網上虛擬會議的方式舉行，有關大會或其任何 續會或延會之通告載於本通函第N-I-1至N-I-2頁。 適用於臨時股東會之H股股東代表委任表格可於本公司網站( https://www.biocytogen.com.cn )及香港交易及 結算所有限公司網站( www.hkexnews.hk )下載。本公司建議H股股東應盡快，但無論如何不遲於臨時股東 會或其任何續會（視情況而定）指定舉行時間前24小時（即不遲於2026年2月 ...

百奧賽圖（北京）醫藥科技股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 建議委任非執行董事 百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 欣然宣布，經董事會提名委員會提名及董事會審議，董事會於2026年1月27日舉 行的董事會會議上建議委任劉弘康先生（「劉先生」）為非執行董事。 有關劉先生的履歷詳情載列如下： 劉弘康先生，35歲，自2021年6月起加入國投創業投資管理有限公司，目前擔任 該公司投資經理。劉先生分別於2012年及2020年獲得中國華中科技大學生物技術 學士學位及生物物理學博士學位。 於本公告日期，除上文所披露者外，劉先生確認(i)彼並無於本公司或本公司任何 其他成員公司擔任任何職位；(ii)彼於過往三年內並無在其證券於香港或海 ...

证券日报网讯 1月27日，百奥赛图发布公告称，同意提名刘弘康先生为公司第二届董事会非执行董事候 选人。 ...

（股份代號：2315） 暫停辦理H股過戶登記手續 百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，本公司將於2026年2月12日（星期四）下午二時正假座中國北京市大興 區大興生物醫藥產業基地寶參南街12號院會議室以現場會議結合網上虛擬會議的 方式舉行本公司臨時股東大會（「臨時股東大會」）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 百奧賽圖（北京）醫藥科技股份有限公司 董事長、首席執行官兼執行董事 沈月雷 香港，2026年1月26日 於本公告日期，董事會包括董事長、首席執行官兼執行董事沈月雷博士、執行董 事倪健博士；非執行董事周可祥博士及張蕾娣女士；獨立非執行董事華風茂先 生、喻長遠博士及梁曉燕女士；及職工董事李妍女士。 為釐 ...

Core Insights - The report highlights the significant presence of public funds in the stock market, with 2,977 stocks appearing in fund heavy positions as of the end of Q4 last year, indicating a clear trend in institutional investment strategies [1] - A total of 107 stocks have a fund holding ratio exceeding 10%, showcasing the high influence and control of institutional funds over these stocks [1] Group 1: Fund Holdings and Stock Performance - Among the 107 stocks with over 10% fund holdings, 56 saw increased investments in Q4, with notable increases in holdings for ShenGong Co., Tianhua New Energy, and Maiwei Co., with increases of 59,020.96%, 15,808.35%, and 959.13% respectively, indicating strong institutional confidence in their fundamentals [2] - Conversely, 48 stocks experienced reductions in fund holdings, with notable decreases for Nuocheng Jianhua-U, Kaiter Co., and Keda Li, with reductions of 43.91%, 41.04%, and 39.95% respectively [2] - Three new stocks entered the heavy holding category, with Baiao Saitu, Litong Technology, and Xingtou Measurement Control having fund holding ratios of 21.55%, 12.60%, and 10.03% respectively [2] Group 2: Institutional Investment Trends - The phenomenon of institutional clustering remains significant, with over 100 funds holding 42 of the 107 stocks, and 29 stocks held by 50 to 99 funds, indicating a strong consensus among institutional investors [4] - Notably, Ningde Times, despite a holding ratio of 11.63%, has the highest number of fund holders at 2,056, followed by Zhongji Xuchuang, Zijin Mining, and Xinyi with over 1,300 fund holders each [4] - The stocks with high fund holdings are predominantly in the "hard technology" and "innovation" sectors, with 42 from the Sci-Tech Innovation Board, 27 from the Growth Enterprise Market, and 31 from the Shanghai and Shenzhen main boards, reflecting a focus on growth sectors [4] Group 3: Performance Expectations - Among the 107 stocks, 26 have released performance forecasts for 2025, with 18 expecting profit increases, 4 expecting declines, and 2 forecasting losses, indicating a generally positive outlook [5] - The highest expected profit growth is for Baiwei Storage at 473.71%, followed by Changxin Bochuang and Baiao Saitu with expected growths of 378.70% and 303.57% respectively, providing strong support for long-term fund holdings [5] - The concentration of fund holdings in the electronics and biopharmaceutical sectors suggests an increased market expectation for technological innovation and consumer recovery [5]

百奥赛图以"抗体货架"为核心的创新模式，打破传统抗体开发的效率瓶颈，成为公司差异化竞争的核心 引擎。抗体开发业务收入从2022年1.27亿元增长至2024年3.18亿元，CAGR高达58%，2024年毛利率超 90%。百万级抗体序列库既可为全球合作伙伴提供即取即用的高质量抗体分子，又能通过授权、合作开 发等多元模式实现技术价值最大化。自主推进的核心管线聚焦高价值赛道，与合作管线形成互补，逐步 兑现商业化潜力，打造新增长引擎。 催化剂 国泰海通证券发布研报称，首次覆盖，给予百奥赛图-B(02315)"增持"评级。公司作为全球领先的创新 药临床前CRO及生物技术公司，技术壁垒深厚，临床前产品与服务收入稳定增长，"千鼠万抗"计划进入 兑现期。预计2025-2027年EPS分别0.38/0.74/1.21元，同比增长411.08%/91.82%/64.10%。参考PE及PS两 种估值，采取谨慎性原则，给予公司目标价57.72元/股，对应2026年PE 78X。 国泰海通证券主要观点如下： 临床前产品与服务打牢基本盘，业务收入高速增长 公司具有领先的基因编辑技术，自主研发CRISPR/EGE、SUPCE等核心技术，打造 ...

国泰海通证券发布研报称，首次覆盖，给予百奥赛图-B(02315)"增持"评级。公司作为全球领先的创新 药临床前CRO及生物技术公司，技术壁垒深厚，临床前产品与服务收入稳定增长，"千鼠万抗"计划进入 兑现期。预计2025-2027年EPS分别0.38/0.74/1.21元，同比增长411.08%/91.82%/64.10%。参考PE及PS两 种估值，采取谨慎性原则，给予公司目标价57.72元/股，对应2026年PE78X。 国泰海通证券主要观点如下： 临床前产品与服务打牢基本盘，业务收入高速增长 公司具有领先的基因编辑技术，自主研发CRISPR/EGE、SUPCE等核心技术，打造了全球人源化程度最 高的全人抗体小鼠平台。模式动物与药理药效评估作为创新药研发的刚需环节，依托全球领先的模型库 与国际标准服务能力，成为公司稳定现金流支柱。模式动物销售额由2021年的0.66亿元增长至2024年的 3.89亿元，营收CAGR超50%。公司客户优质，持续加码全球化布局，与全球前十大药企均建立长期合 作，累计服务950+全球合作伙伴，完成6350+药物评估项目，临床前药理药效评估客户留存率维持60% 以上；海外布局早、设施 ...

Core Viewpoint - The company BaiO Saite-B (02315) has seen a nearly 7% increase in stock price, attributed to the completion of the localization of its AI-driven antibody drug research platform, which enhances its core business collaboration with the QianShu WanKang program [1] Group 1 - BaiO Saite-B's stock price rose by 5.08% to HKD 39.72, with a trading volume of HKD 28.32 million [1] - The company announced the successful localization of its AI-driven antibody drug research platform, which is now fully integrated with its core business initiatives [1] - The ongoing integration of the QianShu WanKang program with the AI system is expected to provide global pharmaceutical companies with more efficient research tools and a richer antibody molecule library [1] Group 2 - The advancements in AI localization are aimed at improving the research efficiency of preclinical PCC molecules for pharmaceutical partners [1] - This development is anticipated to propel the antibody discovery business into a new phase of growth [1]

Core Viewpoint - The company has successfully localized its AI-driven antibody drug development platform, enhancing collaboration with its core business, the "Thousand Mice and Ten Thousand Antibodies" initiative [1] Group 1: Company Developments - The company’s stock has seen a significant increase, rising nearly 7% and currently trading at 39.72 HKD with a transaction volume of 28.32 million HKD [1] - The localization of the AI platform aims to build an intelligent system for antibody drug development, which is expected to improve efficiency in preclinical PCC molecule development for global pharmaceutical partners [1] Group 2: Strategic Initiatives - The integration of the "Thousand Mice and Ten Thousand Antibodies" plan with the AI system is ongoing, which will provide pharmaceutical companies with more efficient research tools and a richer library of antibody molecules [1] - This strategic move is anticipated to propel the antibody discovery business into a new phase of development [1]

Core Viewpoint - Baiaosaitu-B (02315) has seen a significant increase in stock price, rising nearly 7% and currently trading at 39.72 HKD, with a transaction volume of 28.32 million HKD. The company has completed the localization of its AI-driven antibody drug development platform, enhancing synergy with its core business, the "Thousand Mice and Ten Thousand Antibodies" initiative [1]. Group 1 - The company has successfully localized its AI-driven antibody drug development platform [1]. - The integration of the AI system with the "Thousand Mice and Ten Thousand Antibodies" plan is ongoing, which is expected to provide more efficient research tools and a richer antibody molecule library for global pharmaceutical companies [1]. - This development aims to improve the efficiency of preclinical PCC molecule research for pharmaceutical partners, marking a new phase in the antibody discovery business [1].